Table 2.
Factors associated with the development of complications (perforation, migration, and stent re-occlusion)
| Variables |
Complication |
P value | |||
|
Yes |
No |
||||
| Mean | 95%CI | Mean | 95%CI | ||
| Age | 70 | 58.37-81.63 | 66.97 | 62.60- 71.34 | 0.56 |
| Sex | |||||
| Male | 12.82% | 2.00%-23.64% | 87.18% | 76.36%-98.00% | 0.17 |
| Female | 25.80% | 9.87%-41.74% | 74.19% | 58.26%-90.13% | |
| Hemoglobin | 106 | 73-140 | 102 | 92-114 | 0.84 |
| Platelet count | 287 | 176-398 | 271 | 234-308 | 0.38 |
| Creatinine | 90 | 76-104 | 93 | 73-113 | 0.76 |
| Urea | 5.44 | 2.78-8.09 | 7.04 | 4.77-9.32 | 0.83 |
| Albumin | 29.31 | 25.11-33.50 | 30.49 | 28.56-32.43 | 0.59 |
| Alanine aminotransferase | 53 | 17-88 | 34 | 30-37 | 0.28 |
| Aspartate aminotransferase | 86 | 7-165 | 28 | 21-34 | 0.13 |
| Alkaline phosphatase | 439 | 1-930 | 144 | 92-196 | 0.21 |
| Total bilirubin | 37 | 1-88 | 13 | 8-17 | 0.33 |
| International normalized ratio | 1.15 | 1.06-1.24 | 1.44 | 1.19-1.68 | 0.03 |
| Carcinoembryonic antigen | 188 | 0-439 | 69 | 19-148 | 0.32 |
| Length of stenosis (cm) | 5.43 | 4.75-6.11 | 5.09 | 4.24-5.93 | 0.49 |
| Duration between symptoms and stenting (d) | 5 | 1.62-8.38 | 4.59 | 2.94-6.24 | 0.80 |
| Duration between stenting and surgery (d) | 51.33 | 10.96-91.70 | 28.34 | 11.76-44.93 | 0.26 |
| Neo-adjuvant chemotherapy | 17.14% | 4.22%-30.07% | 22.22% | 5.92%-38.53% | 0.62 |
| Number of stents | 1.15 | 0.93-1.38 | 1.1 | 1.03-1.20 | 0.66 |